Theme:
Light Dark Auto
GeneralTop StoriesPoliticsBusinessEconomyTechnologyInternationalEnvironmentScienceSportsHealthEducationEntertainmentLifestyleCultureCrime & LawTravel & TourismFood & RecipesFact CheckReligion
POLITICS
Neutral Sentiment

Trump FDA Chief Marty Makary Resigns After Turmoil

Read, Watch or Listen

Media Bias Meter
Sources: 8
Center 86%
Right 14%
Sources: 8

Washington: Dr. Marty Makary resigned Tuesday as commissioner of the U.S. Food and Drug Administration, just over a year after taking the post. The resignation came after backlash from health industry executives, anti-abortion activists and other allies of President Donald Trump. Officials have not given an official reason for his departure; a White House official told FOX News the move related to "process at the FDA" and said there was "no bad blood" between Makary and the president. Kyle Diamantis, the FDA's deputy commissioner for Food, will serve as acting commissioner, according to FOX. Makary's tenure lasted just over a year; his resignation ends his leadership role and places Diamantis in the acting post while the agency proceeds under interim leadership.

Prepared by Lauren Mitchell and reviewed by editorial team.

Timeline of Events

  • March 2025: Marty Makary confirmed as FDA commissioner by the Senate.
  • 2025–early 2026: Agency experiences mass layoffs, leadership changes, and policy controversies.
  • Early May 2026: Reports indicate White House approved a plan to remove Makary.
  • Tuesday, May 2026: Makary resigns from the FDA; announcement reported by multiple outlets.
  • Immediately after: Kyle Diamantis (Diamantas) named acting FDA commissioner.

Why This Matters to You

The FDA oversees food and drug safety, directly impacting your health. Leadership changes can shift priorities and policies. Keep an eye on any new decisions from Acting Commissioner Diamantis.

The Bottom Line

Makary's resignation ends a turbulent year at the FDA. The agency now moves forward under Diamantis, whose actions will shape its future direction. Worth forwarding if you know someone in the health industry.

Media Bias
Articles Published:
7
Right Leaning:
1
Left Leaning:
0
Neutral:
6

Who Benefited

Certain political allies and advocacy groups critical of Makary, including pro-life organizations and industry stakeholders pressing for regulatory changes, may temporarily regain influence in shaping FDA priorities following his resignation.

Who Impacted

Patients, healthcare providers, FDA career staff, and industry stakeholders face short-term uncertainty in regulatory decision-making and potential delays in drug and device approvals after Makary's departure.

Media Bias
Articles Published:
7
Right Leaning:
1
Left Leaning:
0
Neutral:
6
Distribution:
Left 0%, Center 86%, Right 14%
Who Benefited

Certain political allies and advocacy groups critical of Makary, including pro-life organizations and industry stakeholders pressing for regulatory changes, may temporarily regain influence in shaping FDA priorities following his resignation.

Who Impacted

Patients, healthcare providers, FDA career staff, and industry stakeholders face short-term uncertainty in regulatory decision-making and potential delays in drug and device approvals after Makary's departure.

Coverage of Story:

From Left

No left-leaning sources found for this story.

From Center

Trump FDA Chief Marty Makary Resigns After Turmoil

FOX 5 New York vinnews.com WAOW WSBT PBS.org LatestLY
From Right

BREAKING: Embattled FDA Chief Marty Makary Resigns Amid Mounting Criticism

The Daily Wire

Related News

Comments

JQJO App
Get JQJO App
Read news faster on our app
GET